US EditionLilly Announces Details of Presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
- Eli Lilly and Company announced it will present data from multiple studies at the American Diabetes Association's 85th Scientific Sessions in Chicago from June 20-23, 2025.
- This event follows Lilly's ongoing Phase 3 trials of investigational drugs including orforglipron, insulin efsitora alfa, retatrutide, and bimagrumab targeting type 2 diabetes, obesity, and related conditions.
- Lilly will showcase findings from the ACHIEVE-1 trial for orforglipron, the QWINT series of trials for efsitora, and the BELIEVE trial for bimagrumab during ADA-sponsored sessions. Additionally, the company plans to hold an investor event on Sunday evening, June 22, at 6:30 p.m. Central Time, which will be available to watch live via webcast.
- Approved drugs tirzepatide will also be discussed, noting side effects like nausea and possible thyroid tumors, with doses administered via injectable pens.
- The presentations highlight Lilly's ongoing efforts to redefine diabetes care and treat obesity, though significant risks remain in drug development and regulatory approval processes.
39 Articles
39 Articles
Rutland Herald
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
INDIANAPOLIS, May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American Diabetes Association's (ADA)…
What You Need to Know About the Cost of Mounjaro Pens for Type 2 Diabetes
Managing type 2 diabetes goes beyond diet and exercise—it often involves choosing the right medication. One of the most promising new drugs on the market is Mounjaro (tirzepatide), an injectable treatment that has gained attention for its dual-action benefits in blood sugar control and weight management. But as more people turn to this treatment, a common concern arises: What is the Mounjaro pen cost, and is it accessible to everyone who needs i…
Coverage Details
Bias Distribution
- 50% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
